Snapshot · Sep 14, 2026Public view
Boston, Money-in-Motion.
561 real households across 130 Boston employers, each caught at a vest, exit, relocation, or Money-in-Motion moment. 367 show by default: confirmed titles, events inside 18 months. Names are masked and titles show as their tier in this public view. 12 rows are reveal-ready.
3,256
households scored for our $1.8B pilot firm, within four days
20 of 20
events confirmed in the first delivery
130 of 137
audited events confirmed, none false
1 firm
per household, routed, never sold to three
$15K
first-year advisor revenue per client at $3M and 50 bps
Presets
Signal367 of 367
001
HH-0001
Greater Boston
Tier A title (VP, director, principal)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
125
002
HH-0002
Greater Boston
Tier A title (VP, director, principal)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
125
003
HH-0003
Greater Boston
Tier A title (VP, director, principal)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
125
004
HH-0004
Greater Boston
Tier A title (VP, director, principal)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
125
005
HH-0005
Boston
Tier A title (VP, director, principal)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
125
006
HH-0006
Greater Boston
Tier A title (VP, director, principal)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
125
007
HH-0007
Newton Highlands
Tier A title (VP, director, principal)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
125
008
HH-0008
Wakefield
Tier A title (VP, director, principal)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
125
009
HH-0009
Greater Boston
Tier A title (VP, director, principal)
Avalyn Pharma
YIPO Apr 29 2026 ($300M)
123
010
HH-0010
Boston
Tier A title (VP, director, principal)
Avalyn Pharma
YIPO Apr 29 2026 ($300M)
123
011
HH-0011
Greater Boston
Tier A title (VP, director, principal)
Hemab Therapeutics
YIPO Apr 30 2026 ($301.5M)
123
012
HH-0012
Greater Boston
Tier A title (VP, director, principal)
Hemab Therapeutics
YIPO Apr 30 2026 ($301.5M)
123
013
HH-0013
North Andover
Tier A title (VP, director, principal)
Aktis Oncology
YIPO Jan 2026 ($318M at $18)
120
014
HH-0014
Greater Boston
Tier A title (VP, director, principal)
Aktis Oncology
YIPO Jan 2026 ($318M at $18)
120
015
HH-0015
Boston
Tier A title (VP, director, principal)
Aktis Oncology
YIPO Jan 2026 ($318M at $18)
120
016
HH-0016
Greater Boston
Tier A title (VP, director, principal)
Aktis Oncology
YIPO Jan 2026 ($318M at $18)
120
017
HH-0017
Greater Boston
Tier A title (VP, director, principal)
Merlin Labs · MRLN
YSPAC merger closed Mar 2026, Nasdaq MRLN
116
018
HH-0018
Boston
Tier A title (VP, director, principal)
Merlin Labs · MRLN
YSPAC merger closed Mar 2026, Nasdaq MRLN
116
019
HH-0019
Greater Boston
Tier A title (VP, director, principal)
Circle · CRCL
YIPO Jun 2025 (NYSE: CRCL)
114
020
HH-0020
Greater Boston
Tier A title (VP, director, principal)
Circle · CRCL
YIPO Jun 2025 (NYSE: CRCL)
114
021
HH-0021
Boston
Tier A title (VP, director, principal)
Blueprint Medicines · SNY
YSanofi acquired Blueprint ($129/sh + CVR, ~$9.5B)
111
022
HH-0022
Burlington
Tier A title (VP, director, principal)
Blueprint Medicines · SNY
YSanofi acquired Blueprint ($129/sh + CVR, ~$9.5B)
111
023
HH-0023
Cambridge
Tier A title (VP, director, principal)
Blueprint Medicines · SNY
YSanofi acquired Blueprint ($129/sh + CVR, ~$9.5B)
111
024
HH-0024
Greater Boston
Tier A title (VP, director, principal)
Verve Therapeutics · LLY
YLilly acquired Verve ($10.50/sh + CVR, ~$1.3B)
110
025
HH-0025
Greater Boston
Tier A title (VP, director, principal)
Verve Therapeutics · LLY
YLilly acquired Verve ($10.50/sh + CVR, ~$1.3B)
110
026
HH-0026
Boston
Tier A title (VP, director, principal)
Verve Therapeutics · LLY
YLilly acquired Verve ($10.50/sh + CVR, ~$1.3B)
110
027
HH-0027
Greater Boston
Tier B title (senior manager, lead)
Vestmark
YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). …
109
028
HH-0028
Greater Boston
Tier A title (VP, director, principal)
Sage Therapeutics · SUPN
YSupernus acquired Sage ($8.50/sh + CVR)
108
029
HH-0029
Greater Boston
Tier A title (VP, director, principal)
Sage Therapeutics · SUPN
YSupernus acquired Sage ($8.50/sh + CVR)
108
030
HH-0030
Greater Boston
Tier A title (VP, director, principal)
Sage Therapeutics · SUPN
YSupernus acquired Sage ($8.50/sh + CVR)
108
034
HH-0034
Greater Boston
Tier B title (senior manager, lead)
Hemab Therapeutics
YIPO Apr 30 2026 ($301.5M)
107
036
HH-0036
Boston
Tier A title (VP, director, principal)
Vertex Pharmaceuticals · VRTX
HRelocation (moved to Boston from Bay Area (CA))
106
037
HH-0037
Greater Boston
Tier B title (senior manager, lead)
Aktis Oncology
YIPO Jan 2026 ($318M at $18)
104
041
HH-0041
Greater Boston
Tier A title (VP, director, principal)
Apellis Pharmaceuticals · BIIB
YBiogen acquired Apellis for $41/sh cash ($5.6B)
104
042
HH-0042
Greater Boston
Tier A title (VP, director, principal)
Apellis Pharmaceuticals · BIIB
YBiogen acquired Apellis for $41/sh cash ($5.6B)
104
043
HH-0043
Greater Boston
Tier A title (VP, director, principal)
Apellis Pharmaceuticals · BIIB
YBiogen acquired Apellis for $41/sh cash ($5.6B)
104
044
HH-0044
Waltham
Tier B title (senior manager, lead)
Apellis Pharmaceuticals · BIIB
YBiogen acquired Apellis for $41/sh cash ($5.6B)
104
045
HH-0045
Greater Boston
Tier A title (VP, director, principal)
Apellis Pharmaceuticals · BIIB
YBiogen acquired Apellis for $41/sh cash ($5.6B)
104
056
HH-0056
Greater Boston
Tier B title (senior manager, lead)
Blueprint Medicines · SNY
YSanofi acquired Blueprint ($129/sh + CVR, ~$9.5B)
95
059
HH-0059
Greater Boston
Tier B title (senior manager, lead)
Verve Therapeutics · LLY
YLilly acquired Verve ($10.50/sh + CVR, ~$1.3B)
94
064
HH-0064
Greater Boston
Tier A title (VP, director, principal)
Hologic · HOLX
NRSU / equity vest cycle
94
065
HH-0065
Greater Boston
Tier A title (VP, director, principal)
Hologic · HOLX
NRSU / equity vest cycle
94
066
HH-0066
Greater Boston
Tier A title (VP, director, principal)
Hologic · HOLX
NRSU / equity vest cycle
94
067
HH-0067
Greater Boston
Tier A title (VP, director, principal)
Hologic · HOLX
NRSU / equity vest cycle
94
068
HH-0068
Greater Boston
Tier A title (VP, director, principal)
Hologic · HOLX
NRSU / equity vest cycle
94
072
HH-0072
Boston
Tier A title (VP, director, principal)
Advent International
NComp step-up / deferred comp accrual
93
073
HH-0073
Greater Boston
Tier A title (VP, director, principal)
Advent International
NComp step-up / deferred comp accrual
93
074
HH-0074
Greater Boston
Tier A title (VP, director, principal)
Bain Capital
NComp step-up / deferred comp accrual
93
075
HH-0075
Boston
Tier A title (VP, director, principal)
Bain Capital Credit
NComp step-up / deferred comp accrual
93
076
HH-0076
Boston
Tier A title (VP, director, principal)
Bain Capital
NComp step-up / deferred comp accrual
93
077
HH-0077
Greater Boston
Tier A title (VP, director, principal)
Advent International
NComp step-up / deferred comp accrual
93
078
HH-0078
Boston
Tier A title (VP, director, principal)
Bain Capital Double Impact
NComp step-up / deferred comp accrual
93
079
HH-0079
Greater Boston
Tier A title (VP, director, principal)
Bain Capital Double Impact
NComp step-up / deferred comp accrual
93
080
HH-0080
Boston
Tier A title (VP, director, principal)
Bain Capital Tech Opportunities
NComp step-up / deferred comp accrual
93
081
HH-0081
Greater Boston
Tier B title (senior manager, lead)
Sage Therapeutics · SUPN
YSupernus acquired Sage ($8.50/sh + CVR)
92
093
HH-0093
Cambridge
Tier A title (VP, director, principal)
Alnylam Pharmaceuticals · ALNY
NRSU / equity vest cycle
92
094
HH-0094
Boston
Tier A title (VP, director, principal)
Vertex Pharmaceuticals · VRTX
NRSU / equity vest cycle
92
095
HH-0095
Greater Boston
Tier A title (VP, director, principal)
Klaviyo · KVYO
NRSU / equity vest cycle
92
096
HH-0096
Greater Boston
Tier A title (VP, director, principal)
Klaviyo · KVYO
NRSU / equity vest cycle
92
097
HH-0097
Greater Boston
Tier A title (VP, director, principal)
Arrowstreet Capital
NComp step-up / deferred comp accrual
92
| Household | Title & employer | Pass · trigger | Score · band | Event clock | |
|---|---|---|---|---|---|
001 HH-0001 Greater Boston | Tier A title (VP, director, principal) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 125 HENRY core | Announced 10 days ago | |
002 HH-0002 Greater Boston | Tier A title (VP, director, principal) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 125 HENRY core | Announced 10 days ago | |
003 HH-0003 Greater Boston | Tier A title (VP, director, principal) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 125 Upper · graduation candidate | Announced 10 days ago | |
004 HH-0004 Greater Boston | Tier A title (VP, director, principal) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 125 Upper · graduation candidate | Announced 10 days ago | |
005 HH-0005 Boston | Tier A title (VP, director, principal) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 125 HENRY core | Announced 10 days ago | |
006 HH-0006 Greater Boston | Tier A title (VP, director, principal) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 125 HENRY core | Announced 10 days ago | |
007 HH-0007 Newton Highlands | Tier A title (VP, director, principal) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 125 HENRY core | Announced 10 days ago | |
008 HH-0008 Wakefield | Tier A title (VP, director, principal) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 125 HENRY core | Announced 10 days ago | |
009 HH-0009 Greater Boston | Tier A title (VP, director, principal) Avalyn Pharma | YIPO Apr 29 2026 ($300M) | 123 HENRY core | Lockup in 37 days | |
010 HH-0010 Boston | Tier A title (VP, director, principal) Avalyn Pharma | YIPO Apr 29 2026 ($300M) | 123 Upper · graduation candidate | Lockup in 37 days | |
011 HH-0011 Greater Boston | Tier A title (VP, director, principal) Hemab Therapeutics | YIPO Apr 30 2026 ($301.5M) | 123 HENRY core | Lockup in 38 days | |
012 HH-0012 Greater Boston | Tier A title (VP, director, principal) Hemab Therapeutics | YIPO Apr 30 2026 ($301.5M) | 123 Upper · graduation candidate | Lockup in 38 days | |
013 HH-0013 North Andover | Tier A title (VP, director, principal) Aktis Oncology | YIPO Jan 2026 ($318M at $18) | 120 HENRY core | Lockup 2 months ago | |
014 HH-0014 Greater Boston | Tier A title (VP, director, principal) Aktis Oncology | YIPO Jan 2026 ($318M at $18) | 120 Upper · graduation candidate | Lockup 2 months ago | |
015 HH-0015 Boston | Tier A title (VP, director, principal) Aktis Oncology | YIPO Jan 2026 ($318M at $18) | 120 HENRY core | Lockup 2 months ago | |
016 HH-0016 Greater Boston | Tier A title (VP, director, principal) Aktis Oncology | YIPO Jan 2026 ($318M at $18) | 120 HENRY core | Lockup 2 months ago | |
017 HH-0017 Greater Boston | Tier A title (VP, director, principal) Merlin Labs · MRLN | YSPAC merger closed Mar 2026, Nasdaq MRLN | 116 HENRY core | Closed 6 months ago | |
018 HH-0018 Boston | Tier A title (VP, director, principal) Merlin Labs · MRLN | YSPAC merger closed Mar 2026, Nasdaq MRLN | 116 HENRY core | Closed 6 months ago | |
019 HH-0019 Greater Boston | Tier A title (VP, director, principal) Circle · CRCL | YIPO Jun 2025 (NYSE: CRCL) | 114 HENRY core | Lockup 9 months ago | |
020 HH-0020 Greater Boston | Tier A title (VP, director, principal) Circle · CRCL | YIPO Jun 2025 (NYSE: CRCL) | 114 HENRY core | Lockup 9 months ago | |
021 HH-0021 Boston | Tier A title (VP, director, principal) Blueprint Medicines · SNY | YSanofi acquired Blueprint ($129/sh + CVR, ~$9.5B) | 111 HENRY core | Closed 1.2 years ago | |
022 HH-0022 Burlington | Tier A title (VP, director, principal) Blueprint Medicines · SNY | YSanofi acquired Blueprint ($129/sh + CVR, ~$9.5B) | 111 HENRY core | Closed 1.2 years ago | |
023 HH-0023 Cambridge | Tier A title (VP, director, principal) Blueprint Medicines · SNY | YSanofi acquired Blueprint ($129/sh + CVR, ~$9.5B) | 111 HENRY core | Closed 1.2 years ago | |
024 HH-0024 Greater Boston | Tier A title (VP, director, principal) Verve Therapeutics · LLY | YLilly acquired Verve ($10.50/sh + CVR, ~$1.3B) | 110 HENRY core | Closed 1.2 years ago | |
025 HH-0025 Greater Boston | Tier A title (VP, director, principal) Verve Therapeutics · LLY | YLilly acquired Verve ($10.50/sh + CVR, ~$1.3B) | 110 HENRY core | Closed 1.2 years ago | |
026 HH-0026 Boston | Tier A title (VP, director, principal) Verve Therapeutics · LLY | YLilly acquired Verve ($10.50/sh + CVR, ~$1.3B) | 110 HENRY core | Closed 1.2 years ago | |
027 HH-0027 Greater Boston | Tier B title (senior manager, lead) Vestmark | YEnvestnet announced acquisition of Vestmark Sept 9 2026 (Wakefield MA). … | 109 HENRY core | Announced 10 days ago | |
028 HH-0028 Greater Boston | Tier A title (VP, director, principal) Sage Therapeutics · SUPN | YSupernus acquired Sage ($8.50/sh + CVR) | 108 HENRY core | Closed 1.2 years ago | |
029 HH-0029 Greater Boston | Tier A title (VP, director, principal) Sage Therapeutics · SUPN | YSupernus acquired Sage ($8.50/sh + CVR) | 108 Upper · graduation candidate | Closed 1.2 years ago | |
030 HH-0030 Greater Boston | Tier A title (VP, director, principal) Sage Therapeutics · SUPN | YSupernus acquired Sage ($8.50/sh + CVR) | 108 HENRY core | Closed 1.2 years ago | |
034 HH-0034 Greater Boston | Tier B title (senior manager, lead) Hemab Therapeutics | YIPO Apr 30 2026 ($301.5M) | 107 HENRY core | Lockup in 38 days | |
036 HH-0036 Boston | Tier A title (VP, director, principal) Vertex Pharmaceuticals · VRTX | HRelocation (moved to Boston from Bay Area (CA)) | 106 HENRY core | Relocated 2026 | |
037 HH-0037 Greater Boston | Tier B title (senior manager, lead) Aktis Oncology | YIPO Jan 2026 ($318M at $18) | 104 HENRY core | Lockup 2 months ago | |
041 HH-0041 Greater Boston | Tier A title (VP, director, principal) Apellis Pharmaceuticals · BIIB | YBiogen acquired Apellis for $41/sh cash ($5.6B) | 104 HENRY core | Closed 4 months ago | |
042 HH-0042 Greater Boston | Tier A title (VP, director, principal) Apellis Pharmaceuticals · BIIB | YBiogen acquired Apellis for $41/sh cash ($5.6B) | 104 Upper · graduation candidate | Closed 4 months ago | |
043 HH-0043 Greater Boston | Tier A title (VP, director, principal) Apellis Pharmaceuticals · BIIB | YBiogen acquired Apellis for $41/sh cash ($5.6B) | 104 HENRY core | Closed 4 months ago | |
044 HH-0044 Waltham | Tier B title (senior manager, lead) Apellis Pharmaceuticals · BIIB | YBiogen acquired Apellis for $41/sh cash ($5.6B) | 104 HENRY core | Closed 4 months ago | |
045 HH-0045 Greater Boston | Tier A title (VP, director, principal) Apellis Pharmaceuticals · BIIB | YBiogen acquired Apellis for $41/sh cash ($5.6B) | 104 HENRY core | Closed 4 months ago | |
056 HH-0056 Greater Boston | Tier B title (senior manager, lead) Blueprint Medicines · SNY | YSanofi acquired Blueprint ($129/sh + CVR, ~$9.5B) | 95 HENRY core | Closed 1.2 years ago | |
059 HH-0059 Greater Boston | Tier B title (senior manager, lead) Verve Therapeutics · LLY | YLilly acquired Verve ($10.50/sh + CVR, ~$1.3B) | 94 HENRY core | Closed 1.2 years ago | |
064 HH-0064 Greater Boston | Tier A title (VP, director, principal) Hologic · HOLX | NRSU / equity vest cycle | 94 HENRY core | Quarterly vest cycle | |
065 HH-0065 Greater Boston | Tier A title (VP, director, principal) Hologic · HOLX | NRSU / equity vest cycle | 94 HENRY core | Quarterly vest cycle | |
066 HH-0066 Greater Boston | Tier A title (VP, director, principal) Hologic · HOLX | NRSU / equity vest cycle | 94 HENRY core | Quarterly vest cycle | |
067 HH-0067 Greater Boston | Tier A title (VP, director, principal) Hologic · HOLX | NRSU / equity vest cycle | 94 HENRY core | Quarterly vest cycle | |
068 HH-0068 Greater Boston | Tier A title (VP, director, principal) Hologic · HOLX | NRSU / equity vest cycle | 94 HENRY core | Quarterly vest cycle | |
072 HH-0072 Boston | Tier A title (VP, director, principal) Advent International | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
073 HH-0073 Greater Boston | Tier A title (VP, director, principal) Advent International | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
074 HH-0074 Greater Boston | Tier A title (VP, director, principal) Bain Capital | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
075 HH-0075 Boston | Tier A title (VP, director, principal) Bain Capital Credit | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
076 HH-0076 Boston | Tier A title (VP, director, principal) Bain Capital | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
077 HH-0077 Greater Boston | Tier A title (VP, director, principal) Advent International | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
078 HH-0078 Boston | Tier A title (VP, director, principal) Bain Capital Double Impact | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
079 HH-0079 Greater Boston | Tier A title (VP, director, principal) Bain Capital Double Impact | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
080 HH-0080 Boston | Tier A title (VP, director, principal) Bain Capital Tech Opportunities | NComp step-up / deferred comp accrual | 93 HENRY core | Comp step-up, no equity date | |
081 HH-0081 Greater Boston | Tier B title (senior manager, lead) Sage Therapeutics · SUPN | YSupernus acquired Sage ($8.50/sh + CVR) | 92 HENRY core | Closed 1.2 years ago | |
093 HH-0093 Cambridge | Tier A title (VP, director, principal) Alnylam Pharmaceuticals · ALNY | NRSU / equity vest cycle | 92 Upper · graduation candidate | Quarterly vest cycle | |
094 HH-0094 Boston | Tier A title (VP, director, principal) Vertex Pharmaceuticals · VRTX | NRSU / equity vest cycle | 92 Upper · graduation candidate | Quarterly vest cycle | |
095 HH-0095 Greater Boston | Tier A title (VP, director, principal) Klaviyo · KVYO | NRSU / equity vest cycle | 92 Upper · graduation candidate | Quarterly vest cycle | |
096 HH-0096 Greater Boston | Tier A title (VP, director, principal) Klaviyo · KVYO | NRSU / equity vest cycle | 92 HENRY core | Quarterly vest cycle | |
097 HH-0097 Greater Boston | Tier A title (VP, director, principal) Arrowstreet Capital | NComp step-up / deferred comp accrual | 92 HENRY core | Comp step-up, no equity date |
Showing 60 of 367
Prepared for Boston Fintech Week 2026. Employees of firms in the room are excluded from this view. Unverified titles and events older than 18 months sit behind toggles. Built from public professional profiles and public company filings only. Each household is routed to one firm, never sold to three.